$3.42
Live
0.58%
Downside
Day's Volatility :3.41%
Upside
2.84%
66.08%
Downside
52 Weeks Volatility :74.62%
Upside
25.16%
Period | Rockwell Medical Inc | Index (Russel 2000) |
---|---|---|
3 Months | 77.44% | 0.0% |
6 Months | 128.38% | 0.0% |
1 Year | 103.53% | 0.0% |
3 Years | -44.77% | -23.0% |
Market Capitalization | 111.1M |
Book Value | $0.76 |
Earnings Per Share (EPS) | -0.15 |
PEG Ratio | -0.79 |
Wall Street Target Price | 7.5 |
Profit Margin | -5.06% |
Operating Margin TTM | 1.99% |
Return On Assets TTM | -4.25% |
Return On Equity TTM | -28.9% |
Revenue TTM | 94.4M |
Revenue Per Share TTM | 3.04 |
Quarterly Revenue Growth YOY | 42.9% |
Gross Profit TTM | 4.1M |
EBITDA | -885.0K |
Diluted Eps TTM | -0.15 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.03 |
EPS Estimate Next Year | 0.07 |
EPS Estimate Current Quarter | -0.03 |
EPS Estimate Next Quarter | -0.02 |
What analysts predicted
Upside of 119.3%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 63.4M | ↑ 10.63% |
Net Income | -32.1M | ↑ 23.94% |
Net Profit Margin | -50.68% | ↓ 5.44% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 61.3M | ↓ 3.29% |
Net Income | -31.1M | ↓ 3.26% |
Net Profit Margin | -50.7% | ↓ 0.02% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 62.2M | ↑ 1.46% |
Net Income | -31.9M | ↑ 2.75% |
Net Profit Margin | -51.34% | ↓ 0.64% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 61.9M | ↓ 0.43% |
Net Income | -35.0M | ↑ 9.71% |
Net Profit Margin | -56.57% | ↓ 5.23% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 72.8M | ↑ 17.57% |
Net Income | -20.6M | ↓ 41.26% |
Net Profit Margin | -28.26% | ↑ 28.31% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 83.6M | ↑ 14.84% |
Net Income | -8.4M | ↓ 58.99% |
Net Profit Margin | -10.09% | ↑ 18.17% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 19.7M | ↑ 1.84% |
Net Income | -2.5M | ↓ 10.68% |
Net Profit Margin | -12.51% | ↑ 1.75% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.1M | ↓ 8.07% |
Net Income | -3.3M | ↑ 34.35% |
Net Profit Margin | -18.28% | ↓ 5.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 23.8M | ↑ 31.48% |
Net Income | -1.9M | ↓ 43.36% |
Net Profit Margin | -7.88% | ↑ 10.4% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 22.1M | ↓ 7.06% |
Net Income | -1.5M | ↓ 19.23% |
Net Profit Margin | -6.84% | ↑ 1.04% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 22.7M | ↑ 2.64% |
Net Income | -1.7M | ↑ 14.48% |
Net Profit Margin | -7.63% | ↓ 0.79% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 25.8M | ↑ 13.92% |
Net Income | 343.0K | ↓ 119.82% |
Net Profit Margin | 1.33% | ↑ 8.96% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 52.6M | ↓ 10.59% |
Total Liabilities | 25.3M | ↓ 2.26% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 44.3M | ↓ 15.68% |
Total Liabilities | 24.0M | ↓ 5.08% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 77.7M | ↑ 75.44% |
Total Liabilities | 43.6M | ↑ 81.6% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 48.6M | ↓ 37.52% |
Total Liabilities | 46.0M | ↑ 5.65% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 46.6M | ↓ 3.99% |
Total Liabilities | 32.5M | ↓ 29.34% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 52.2M | ↑ 11.88% |
Total Liabilities | 30.9M | ↓ 5.06% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 40.5M | ↓ 13.22% |
Total Liabilities | 27.9M | ↓ 14.14% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 38.0M | ↓ 6.02% |
Total Liabilities | 28.5M | ↑ 2.07% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 52.6M | ↑ 38.3% |
Total Liabilities | 31.1M | ↑ 9.05% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 52.2M | ↓ 0.82% |
Total Liabilities | 30.9M | ↓ 0.66% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 50.7M | ↓ 2.78% |
Total Liabilities | 30.1M | ↓ 2.6% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 53.0M | ↑ 4.54% |
Total Liabilities | 29.5M | ↓ 1.83% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.4M | ↓ 3.29% |
Investing Cash Flow | 12.7M | ↓ 12.27% |
Financing Cash Flow | 22.0M | ↓ 1116.97% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -27.3M | ↑ 33.47% |
Investing Cash Flow | -4.7M | ↓ 137.33% |
Financing Cash Flow | 21.1M | ↓ 4.17% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -29.6M | ↑ 8.76% |
Investing Cash Flow | 3.2M | ↓ 167.62% |
Financing Cash Flow | 63.3M | ↑ 200.29% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.5M | ↑ 13.13% |
Investing Cash Flow | 311.0K | ↓ 90.32% |
Financing Cash Flow | -2.2M | ↓ 103.44% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -17.4M | ↓ 48.07% |
Investing Cash Flow | -2.4M | ↓ 870.42% |
Financing Cash Flow | 16.6M | ↓ 863.29% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.9M | ↑ 552.53% |
Investing Cash Flow | 5.3M | ↑ 64.76% |
Financing Cash Flow | -631.0K | ↓ 88.53% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.7M | ↓ 55.11% |
Investing Cash Flow | -64.0K | ↓ 101.21% |
Financing Cash Flow | -130.0K | ↓ 79.4% |
Sell
Neutral
Buy
Rockwell Medical Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Rockwell Medical Inc | -11.73% | 128.38% | 103.53% | -44.77% | -87.62% |
Neurocrine Biosciences Inc. | 0.22% | -11.71% | 9.36% | 13.47% | 21.32% |
Haleon Plc Spon Ads | -5.08% | 20.69% | 22.01% | 36.17% | 36.17% |
Zoetis Inc. | -0.16% | 32.8% | 16.08% | -7.35% | 52.85% |
Viatris Inc. | 2.53% | 4.53% | 31.84% | -16.06% | -28.03% |
Catalent, Inc. | 0.9% | 7.56% | 42.8% | -54.43% | 23.98% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Rockwell Medical Inc | NA | NA | -0.79 | -0.03 | -0.29 | -0.04 | NA | 0.76 |
Neurocrine Biosciences Inc. | 35.55 | 35.55 | 0.27 | 4.54 | 0.16 | 0.12 | NA | 24.87 |
Haleon Plc Spon Ads | 32.52 | 32.52 | 1.5 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
Zoetis Inc. | 37.9 | 37.9 | 2.64 | 5.83 | 0.49 | 0.14 | 0.01 | 10.94 |
Viatris Inc. | 224.4 | NA | 0.07 | 2.67 | -0.03 | 0.03 | 0.04 | 16.36 |
Catalent, Inc. | 211.02 | NA | 3.02 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Rockwell Medical Inc | Buy | $111.1M | -87.62% | NA | -5.06% |
Neurocrine Biosciences Inc. | Buy | $11.9B | 21.32% | 35.55 | 16.0% |
Haleon Plc Spon Ads | Buy | $45.6B | 36.17% | 32.52 | 9.66% |
Zoetis Inc. | Buy | $87.6B | 52.85% | 37.9 | 26.29% |
Viatris Inc. | Hold | $14.0B | -28.03% | 224.4 | -4.24% |
Catalent, Inc. | Hold | $10.9B | 23.98% | 211.02 | -23.81% |
Insights on Rockwell Medical Inc
Revenue is up for the last 3 quarters, 22.09M → 25.83M (in $), with an average increase of 7.4% per quarter
Netprofit is up for the last 2 quarters, -1.73M → 343.0K (in $), with an average increase of 604.7% per quarter
Armistice Capital, LLC
Vanguard Group Inc
Perkins Capital Management Inc
Geode Capital Management, LLC
Richmond Brothers Inc
BlackRock Inc
rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www
Organization | Rockwell Medical Inc |
Employees | 237 |
CEO | Dr. Mark Strobeck Ph.D. |
Industry | Health Technology |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$3.42
-1.16%
Invesco Bulletshares 2025 Hi
$3.42
-1.16%
Schwab International Dividend Equity Etf
$3.42
-1.16%
Blockchain Coinvestors Acquisition Corp.
$3.42
-1.16%
Allgiant Travel Company
$3.42
-1.16%
Rogers Corp
$3.42
-1.16%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$3.42
-1.16%
Iheartmedia
$3.42
-1.16%
Lightpath Technologies Inc
$3.42
-1.16%